Efstratios Georgakarakos1, George S Georgiadis2, Christos Argyriou2, Nikolaos Schoretsanitis2, George A Antoniou3, Miltos K Lazarides2. 1. Department of Vascular Surgery, "Democritus" University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece. Electronic address: efstratiosgeorg@gmail.com. 2. Department of Vascular Surgery, "Democritus" University of Thrace, University Hospital of Alexandroupolis, Alexandroupolis, Greece. 3. Department of Vascular and Endovascular Surgery, The Royal Oldham Hospital, The Pennine Acute Hospitals NHS Trust, Manchester, UK.
Abstract
BACKGROUND: Our aim was to present our preliminary experience with the recently introduced Treovance aortic stent-graft device (Bolton Medical, Barcelona, Spain) in the treatment of abdominal aortic aneurysm (AAA). METHODS: Eight patients underwent treatment of an infrarenal AAA (mean maximum diameter, 56.4 ± 6.8 mm) with the Treovance device. Iliac tortuosity was considered mild, moderate, or severe when ≥1 angulation of 45-90°, 1 angulation ≥90°, or ≥2 angulations ≥90°, respectively, were present. RESULTS: Mild angulation of the infrarenal neck (10-45°) was present in 7 patients, whereas the remaining patient had severe infrarenal neck angulation (65°). Three patients had severe iliac tortuosity. Primary technical success was achieved in all but 1 patient in whom a type Ia endoleak was identified on completion angiogram. The endoleak was successfully treated with a proximal aortic cuff. A femoral access complication occurred in 1 patient. Mean follow-up was 6.8 months (range, 1-12). No device-related serious adverse events or rupture occurred during the given follow-up period. The only type II endoleak identified resolved spontaneously within 12 months. CONCLUSIONS: The Treovance abdominal stent-graft system seems to guarantee an accurate, safe, and effective deployment in AAA even through angulated and tortuous iliac vessels. Although our preliminary results are promising, follow-up data are needed to establish the durability of this new-generation endovascular device in standard or challenging anatomies.
BACKGROUND: Our aim was to present our preliminary experience with the recently introduced Treovance aortic stent-graft device (Bolton Medical, Barcelona, Spain) in the treatment of abdominal aortic aneurysm (AAA). METHODS: Eight patients underwent treatment of an infrarenal AAA (mean maximum diameter, 56.4 ± 6.8 mm) with the Treovance device. Iliac tortuosity was considered mild, moderate, or severe when ≥1 angulation of 45-90°, 1 angulation ≥90°, or ≥2 angulations ≥90°, respectively, were present. RESULTS: Mild angulation of the infrarenal neck (10-45°) was present in 7 patients, whereas the remaining patient had severe infrarenal neck angulation (65°). Three patients had severe iliac tortuosity. Primary technical success was achieved in all but 1 patient in whom a type Ia endoleak was identified on completion angiogram. The endoleak was successfully treated with a proximal aortic cuff. A femoral access complication occurred in 1 patient. Mean follow-up was 6.8 months (range, 1-12). No device-related serious adverse events or rupture occurred during the given follow-up period. The only type II endoleak identified resolved spontaneously within 12 months. CONCLUSIONS: The Treovance abdominal stent-graft system seems to guarantee an accurate, safe, and effective deployment in AAA even through angulated and tortuous iliac vessels. Although our preliminary results are promising, follow-up data are needed to establish the durability of this new-generation endovascular device in standard or challenging anatomies.
Authors: Raman Uberoi; Carlo Setacci; Mario Lescan; Antonio Lorido; David Murray; Zoltán Szeberin; Tomasz Zubilewicz; Vincent Riambau; Angsu Chartrungsan; Jörg Tessarek Journal: J Endovasc Ther Date: 2018-10-03 Impact factor: 3.487